|
|
Vol. 16.05 – 18 March, 2025
|
|
|
|
|
|
|
|
Researchers reported a critical neonatal window in mice when microbiota disruption resulted in lifelong metabolic consequences stemming from reduced β cell development.
[Science]
|
|
|
|
|
|
PUBLICATIONSListed by the impact factor of the journal
|
|
|
|
|
|
|
|
The authors showed that a liver-derived secreted protein, Neuregulin1α, promoted compensatory proliferation of pancreatic β cells in type 2 diabetes.
[Nature Communications]
|
|
|
|
|
|
Scientists demonstrated that senescent β-cells of endocrine pancreas decided the onset and severity of chronic and acute pancreatitis.
[Nature Communications]
|
|
|
|
|
|
Investigators explored the novel antidiabetic potential of MCPS-3, a polysaccharide derived from Momordica charantia L., and its underlying mechanisms in a high-fat diet and streptozotocin-induced type 2 diabetes mouse model.
[Journal of Agricultural and Food Chemistry]
|
|
|
|
|
|
|
|
The authors showed that extrachromosomal DNA (ecDNA) was a major source of high-level focal amplification in key oncogenes and a major contributor of MYC heterogeneity in PDAC.
[Nature]
|
|
|
|
|
|
Investigators developed a novel pan-RAS inhibitor, ADT-1004 and evaluated antitumor activity in murine and human PDAC models. ADT-1004 had strong antitumor activity in aggressive and clinically relevant PDAC models with unique selectivity to block RAS-mediated signaling in RAS mutant cells.
[Molecular Cancer]
|
|
|
|
|
|
Researchers combined RNA sequencing and assay for transposase-accessible chromatin using sequencing on sorted pancreatic stellate cells from adjacent normal and PDAC tissues to investigate their transcriptional and epigenetic activation.
[Advanced Science]
|
|
|
|
|
|
Scientists showed that expression of neuropeptide Y (NPY) and NPY1R were upregulated in mouse pancreatic cancer (PC) models and human patients with PC.
[Science Advances]
|
|
|
|
|
|
Through multiple, integrated orthogonal biological approaches in different 2D and 3D PDAC cultures, researchers characterized RS-35d enantiomers, in terms of mode of action and single contributions.
[Cell Death Discovery]
|
|
|
|
|
|
|
|
Investigators provide a comprehensive analysis of the literature on exocrine pancreatic insufficiency etiology, with a thorough overview to support its consideration as a potential diagnosis.
[Gastroenterology Report]
|
|
|
|
|
|
|
|
Anocca AB announced the authorization of its Clinical Trial Application from the regulatory authorities in four European countries under the European Union’s harmonized framework, for VIDAR-1, a Phase I/II multi-product umbrella trial in patients with mutated KRAS-positive advanced pancreatic cancer.
[Anocca AB]
|
|
|
|
|
|
PEP-Therapy announced that the US FDA has granted Orphan Drug designation to its flagship product, PEP-010, for the treatment of pancreatic cancer.
[PEP-Therapy (GlobeNewswire)]
|
|
|
|
|
|
|
|
May 7-9, 2025
Bruges, Belgium
|
|
|
|
|
|
|
|
|
|
|
The Pennsylvania State University – State College, Pennsylvania, United States
|
|
|
|
|
|
|
Upstate Medical University – Syracuse, New York, United States
|
|
|
|
|
|
|
University of British Columbia – Vancouver, British Columbia, Canada
|
|
|
|
|
|
|
The University of Chicago – Chicago, Illinois, United States
|
|
|
|
|
|
|
The University of Pennsylvania – Philadelphia, Pennsylvania, United States
|
|
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
